Why Lantern Pharma Inc.’s (LTRN) Stock Is Down 5.14%
As of Tuesday, July 07, Lantern Pharma Inc.’s LTRN share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Commentary & Analysis
Why Lantern Pharma Inc.’s (LTRN) Stock Is Down 5.04%
As of Wednesday, July 01, Lantern Pharma Inc.’s LTRN share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Lantern Pharma Inc.’s (LTRN) Stock Is Down 5.64%
As of Thursday, June 25, Lantern Pharma Inc.’s LTRN share price has dipped by 5.64%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Lantern Pharma Inc.’s (LTRN) Stock Is Down 10.24%
As of Thursday, August 14, Lantern Pharma Inc.’s LTRN share price has dipped by 10.24%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Lantern Pharma Inc.’s (LTRN) Stock Is Up 5.38%
As of Wednesday, August 06, Lantern Pharma Inc.’s LTRN share price has surged by 5.38%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | LTRN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $29.9 | $292.6 | 12% |
|
| Shares Out (Mil) | 12.4 | 54.4 | 23% |
|
| Institutional Ownership | 79.3% | 93.2% | 48% |
|
| Float (Mil) | 9.8 | 40.2 | 19% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 129 | 544 | 38% |
|
| Price Change (52-week) |
(47.7%) | 59.7% | 15% |
|
| Growth | LTRN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (23.7%) | (10.1%) | 17% |
|
| EPS (5yr) | (2.7%) | 16.0% | 28 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.6%) | (15.6%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.380) | ($1.510) | ($2.020) | |
| Month Ago EPS | ($0.380) | ($1.510) | ($2.020) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.380) | ($1.510) | ($2.020) | |
| Year/Year Chg | (33.3%) | (3.9%) | 34.3% | |
| Financials | LTRN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($19) | ($43) | 24% |
|
| EPS (TTM) | ($1.632) | ($1.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($14) | ($31) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | na | $164 | na |
|
| Valuation | LTRN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | LTRN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (143.4%) | (47.5%) | 3% |
|
| ROE | (400.9%) | (55.0%) | 2% |
|
| Liabilities to Assets | 137.4% | 29.6% | 97% |
|
| F-Score | 1 | 3 | 1% |
|
Lantern Pharma Inc. did not pass any screens on 8/21/2026.
